Studies have shown higher PM prevalence in gastric cancer patients harboring SOX9 and DEK mutations9, colorectal cancer patients with KRAS/BRAF mutations10, and appendiceal cancer patients with GNAS mutations11. This evidence concerns the gene BRAF and colorectal cancer.